Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberta Hoi

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Arthritis Care & Research|April 28, 2026
Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrualKevin Zhang, Eric F Morand, Sarah E Boyd, et al.
Clinical & Translational Immunology|January 1, 2020
A potential association between IL-3 and type I and III interferons in systemic lupus erythematosusShereen Oon, Katherine Monaghan, Milica Ng, et al.
Arthritis Care & Research|July 9, 2019
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus ErythematosusAi Li Yeo, Rachel Koelmeyer, Rangi Kandane-Rathnayake, et al.
Seminars in Arthritis and Rheumatism|September 26, 2022
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysisTina Ko, Rachel Koelmeyer, Ning Li, et al.
Nature Reviews. Rheumatology|August 4, 2021
Global epidemiology of systemic lupus erythematosusMegan R W Barber, Cristina Drenkard, Titilola Falasinnu, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
Rheumatology (Oxford, England)|November 11, 2025
Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Eric F Morand, Richard Furie, Martin Aringer, et al.
Iscience|July 17, 2023
CSL362 potently and specifically depletes pDCs <i>in</i><i>vitro</i> and ablates SLE-immune complex-induced IFN responsesKatherine A Monaghan, Alberta Hoi, Cristina Gamell, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
Annals of the Rheumatic Diseases|October 14, 2015
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Kate Franklyn, Chak Sing Lau, Sandra V Navarra, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Arthritis Care & Research|April 28, 2026
Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrualKevin Zhang, Eric F Morand, Sarah E Boyd, et al.
Clinical & Translational Immunology|January 1, 2020
A potential association between IL-3 and type I and III interferons in systemic lupus erythematosusShereen Oon, Katherine Monaghan, Milica Ng, et al.
Arthritis Care & Research|July 9, 2019
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus ErythematosusAi Li Yeo, Rachel Koelmeyer, Rangi Kandane-Rathnayake, et al.
Seminars in Arthritis and Rheumatism|September 26, 2022
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysisTina Ko, Rachel Koelmeyer, Ning Li, et al.
Nature Reviews. Rheumatology|August 4, 2021
Global epidemiology of systemic lupus erythematosusMegan R W Barber, Cristina Drenkard, Titilola Falasinnu, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
Rheumatology (Oxford, England)|November 11, 2025
Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Eric F Morand, Richard Furie, Martin Aringer, et al.
Iscience|July 17, 2023
CSL362 potently and specifically depletes pDCs <i>in</i><i>vitro</i> and ablates SLE-immune complex-induced IFN responsesKatherine A Monaghan, Alberta Hoi, Cristina Gamell, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
Annals of the Rheumatic Diseases|October 14, 2015
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Kate Franklyn, Chak Sing Lau, Sandra V Navarra, et al.
Pageof 9